GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SELLAS Life Sciences Group Inc (NAS:SLS) » Definitions » Cyclically Adjusted FCF per Share

SLS (SELLAS Life Sciences Group) Cyclically Adjusted FCF per Share : $-1,862.98 (As of Dec. 2024)


View and export this data going back to 2008. Start your Free Trial

What is SELLAS Life Sciences Group Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

SELLAS Life Sciences Group's adjusted free cash flow per share for the three months ended in Dec. 2024 was $-0.097. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-1,862.98 for the trailing ten years ended in Dec. 2024.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 30.00% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 23.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of SELLAS Life Sciences Group was 30.00% per year. The lowest was 9.70% per year. And the median was 15.55% per year.

As of today (2025-03-26), SELLAS Life Sciences Group's current stock price is $1.18. SELLAS Life Sciences Group's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2024 was $-1,862.98. SELLAS Life Sciences Group's Cyclically Adjusted Price-to-FCF of today is .


SELLAS Life Sciences Group Cyclically Adjusted FCF per Share Historical Data

The historical data trend for SELLAS Life Sciences Group's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SELLAS Life Sciences Group Cyclically Adjusted FCF per Share Chart

SELLAS Life Sciences Group Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6,536.55 -5,434.14 -4,431.04 -3,277.99 -1,862.98

SELLAS Life Sciences Group Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3,277.99 -3,004.62 -2,584.60 -2,225.17 -1,862.98

Competitive Comparison of SELLAS Life Sciences Group's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, SELLAS Life Sciences Group's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SELLAS Life Sciences Group's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SELLAS Life Sciences Group's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where SELLAS Life Sciences Group's Cyclically Adjusted Price-to-FCF falls into.



SELLAS Life Sciences Group Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, SELLAS Life Sciences Group's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=-0.097/133.1571*133.1571
=-0.097

Current CPI (Dec. 2024) = 133.1571.

SELLAS Life Sciences Group Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201503 -2,314.800 99.621 -3,094.044
201506 -2,375.200 100.684 -3,141.264
201509 -1,901.400 100.392 -2,521.976
201512 -3,071.200 99.792 -4,098.028
201603 -2,203.667 100.470 -2,920.601
201606 -1,915.167 101.688 -2,507.846
201609 -1,744.000 101.861 -2,279.832
201612 2,506.500 101.863 3,276.550
201703 -152.120 102.862 -196.922
201706 -117.269 103.349 -151.092
201709 -745.615 104.136 -953.410
201712 132.600 104.011 169.757
201803 -45.403 105.290 -57.420
201806 -46.659 106.317 -58.438
201809 -40.127 106.507 -50.168
201812 -10.329 105.998 -12.976
201903 -11.166 107.251 -13.863
201906 -7.207 108.070 -8.880
201909 -0.892 108.329 -1.096
201912 -0.822 108.420 -1.010
202003 -1.072 108.902 -1.311
202006 -0.503 108.767 -0.616
202009 -0.431 109.815 -0.523
202012 0.330 109.897 0.400
202103 -0.690 111.754 -0.822
202106 -0.321 114.631 -0.373
202109 -0.370 115.734 -0.426
202112 -0.313 117.630 -0.354
202203 -0.450 121.301 -0.494
202206 -0.284 125.017 -0.302
202209 -0.279 125.227 -0.297
202212 -0.248 125.222 -0.264
202303 -0.515 127.348 -0.538
202306 -0.267 128.729 -0.276
202309 -0.243 129.860 -0.249
202312 -0.157 129.419 -0.162
202403 -0.240 131.776 -0.243
202406 -0.168 132.554 -0.169
202409 -0.114 133.029 -0.114
202412 -0.097 133.157 -0.097

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


SELLAS Life Sciences Group  (NAS:SLS) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


SELLAS Life Sciences Group Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of SELLAS Life Sciences Group's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


SELLAS Life Sciences Group Business Description

Traded in Other Exchanges
Address
7 Times Square, Suite 2503, New York, NY, USA, 10036
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Executives
Angelos M. Stergiou director, officer: President and CEO C/O SELLAS LIFE SCIENCES GROUP, INC., 2000 CROW CANYON PLACE, SUITE 380, SAN RAMON CA 94583
Barbara A Wood officer: EVP, Gen. Counsel, Corp. Sec. 58 S SERVICE RD, MELVILLE NY 11747
John Thomas Burns officer: VP, Finance & Corp Controller 16760 SW UPPER BOONES FERRY RD, SUITE 101, PORTLAND X1 97224
Katherine Bach Kalin director 3201 CARNEGIE AVENUE, CLEVELAND OH 44115
Robert Francomano officer: Chief Commercial Officer C/O STEMLINE THERAPEUTICS, INC., 750 LEXINGTON AVENUE, 11TH FLOOR, NEW YORK NY 10022
Nicholas J. Sarlis officer: Chief Medical Officer and SVP C/O SELLAS LIFE SCIENCES GROUP, INC., 2000 CROW CANYON PLACE, STE. 380, SAN RAMON CA 94583
Stephen F Ghiglieri director C/O NEUROGESX INC., 981 INDUSTRIAL ROAD SUITE F, SAN CARLOS CA 94070
Jane Wasman director C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
David A Scheinberg director 325 CENTRAL PARK W, APT 38, NEW YORK NY 10025
Van Nostrand Robert L director C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511
John Varian director ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Eqc Private Markets Sac Fund Ltd-eqc Biotech Sely Ii Fund` 10 percent owner C/O EQUILIBRIA CAPITAL MANAGEMENT LTD., ONE BERMUDIANA ROAD, HAMILTON D0 HM08
Eqc Private Markets Sac Fund Ltd-eqc Biotech Sely I Fund 10 percent owner C/O EQUILIBRIA CAPITAL MANAGEMENT LTD., ONE BERMUDIANA ROAD, HAMILTON D0 HM08
Equilibria Capital Management Ltd 10 percent owner O'HARA HOUSE, ONE BERMUDIANA ROAD, HAMILTON D0 HM08
Eqc Private Markets Ii Sac Fund Ltd-eqc Biotech Sely Iii Fund 10 percent owner C/O EQUILIBRIA CAPITAL MANAGEMENT LTD., ONE BERMUDIANA ROAD, HAMILTON D0 HM08

SELLAS Life Sciences Group Headlines